{"schema_version":"1","generated_at":"2026-11-21T21:39:24.556Z","data_as_of":null,"url":"https://www.findmykol.com/kol/jacob-sloane","json_url":"https://www.findmykol.com/kol/jacob-sloane/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"jacob-sloane","name":"Jacob Sloane","credential":"MD, PhD","specialty":"Neurology","specialty_raw":"Neurology","therapeutic_area":"Neurology","therapeutic_areas":["Neurology"],"institution":"Beth Israel Deaconess Medical Center","institution_url":"https://www.findmykol.com/institution/beth-israel-deaconess-medical-center","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"on_file":["npi","orcid","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Jacob Sloane is a Neurology physician affiliated with Beth Israel Deaconess Medical Center. OpenAlex indexes 136 publications with 3,741 citations (h-index 28).","overview":null,"focus":{"indications":[],"research_topics":["Neurology"]},"scholarship":{"works_count":136,"cited_by_count":3741,"h_index":28,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":13,"program_years":{"first":2021,"last":null},"rows_total":36,"shown":3,"withheld":33,"rows":[{"payer":"Genzyme","program_year":2025,"amount_usd":74358.24,"payment_count":3},{"payer":"Novartis","program_year":2025,"amount_usd":592.72,"payment_count":1},{"payer":"GENZYME CORPORATION","program_year":2025,"amount_usd":204.59,"payment_count":2}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":7,"areas_shown":3,"areas":[{"area":"Nervous system","share_pct":62.4,"classes_total":23,"classes":[{"class":"Benzodiazepine","setting":"prescribed","share_pct":11.6,"drugs":[{"name":"Clonazepam","share_pct":40.5},{"name":"Lorazepam","share_pct":32.8},{"name":"Diazepam","share_pct":14.9},{"name":"Alprazolam","share_pct":11.9}],"max_beneficiaries":null},{"class":"Gabapentinoids","setting":"prescribed","share_pct":9.5,"drugs":[{"name":"Gabapentin","share_pct":88.9},{"name":"Pregabalin","share_pct":11.1}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":17.9,"classes_total":6,"classes":[{"class":"Other immunostimulants","setting":"prescribed","share_pct":4.6,"drugs":[{"name":"Copaxone","share_pct":77.9},{"name":"Glatiramer Acetate","share_pct":22.1}],"max_beneficiaries":null},{"class":"Other immunosuppressants","setting":"prescribed","share_pct":4.3,"drugs":[{"name":"Dimethyl Fumarate","share_pct":54},{"name":"Tecfidera","share_pct":30.4},{"name":"Vumerity","share_pct":15.5}],"max_beneficiaries":null}]},{"area":"Musculoskeletal","share_pct":10.4,"classes_total":4,"classes":[{"class":"gamma-Aminobutyric Acid-ergic Agonist","setting":"prescribed","share_pct":7.3,"drugs":[{"name":"Baclofen","share_pct":100}],"max_beneficiaries":57},{"class":"Central alpha-2 Adrenergic Agonist","setting":"prescribed","share_pct":1.1,"drugs":[{"name":"Tizanidine Hcl","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":28.2,"facility_pct":71.8},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Characterization of cortico-meningeal translocator protein expression in multiple sclerosis","year":2024,"journal":"Brain","source_url":"https://doi.org/10.1093/brain/awae030","status":"verified"},{"title":"High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate","year":2023,"journal":"Multiple Sclerosis Journal","source_url":"https://doi.org/10.1177/13524585231189641","status":"verified"},{"title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","year":2022,"journal":"The Lancet Neurology","source_url":"https://doi.org/10.1016/s1474-4422(22)00143-0","status":"verified"},{"title":"Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease","year":2022,"journal":"Multiple Sclerosis and Related Disorders","source_url":"https://doi.org/10.1016/j.msard.2022.103505","status":"verified"},{"title":"Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression","year":2021,"journal":"Brain Communications","source_url":"https://doi.org/10.1093/braincomms/fcab134","status":"verified"}],"source":"works"},"similar":[{"name":"Matcheri Keshavan","slug":"matcheri-keshavan","institution":"Beth Israel Deaconess Medical Center","specialty":"Psychiatry","url":"https://www.findmykol.com/kol/matcheri-keshavan","json_url":"https://www.findmykol.com/kol/matcheri-keshavan/profile.json"},{"name":"Connie Tsao","slug":"connie-tsao","institution":"Beth Israel Deaconess Medical Center","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/connie-tsao","json_url":"https://www.findmykol.com/kol/connie-tsao/profile.json"},{"name":"Donald Cutlip","slug":"donald-cutlip","institution":"Beth Israel Deaconess Medical Center","specialty":"Interventional Cardiology","url":"https://www.findmykol.com/kol/donald-cutlip","json_url":"https://www.findmykol.com/kol/donald-cutlip/profile.json"},{"name":"Robert Yeh","slug":"robert-yeh","institution":"Beth Israel Deaconess Medical Center","specialty":"Interventional Cardiology","url":"https://www.findmykol.com/kol/robert-yeh","json_url":"https://www.findmykol.com/kol/robert-yeh/profile.json"},{"name":"Bruce Miller","slug":"bruce-miller","institution":"University of California, San Francisco (UCSF)","specialty":"Neurology","url":"https://www.findmykol.com/kol/bruce-miller","json_url":"https://www.findmykol.com/kol/bruce-miller/profile.json"},{"name":"David Knopman","slug":"david-knopman","institution":"Mayo Clinic Rochester","specialty":"Neurology","url":"https://www.findmykol.com/kol/david-knopman","json_url":"https://www.findmykol.com/kol/david-knopman/profile.json"},{"name":"Brett Kissela","slug":"brett-kissela","institution":"Medical College of Wisconsin","specialty":"Neurology","url":"https://www.findmykol.com/kol/brett-kissela","json_url":"https://www.findmykol.com/kol/brett-kissela/profile.json"},{"name":"Richard Lipton","slug":"richard-lipton","institution":"Albert Einstein College of Medicine","specialty":"Neurology","url":"https://www.findmykol.com/kol/richard-lipton","json_url":"https://www.findmykol.com/kol/richard-lipton/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":33,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}